方盛制药：子公司瑞卢戈利片获药物临床试验批准

Core Viewpoint - Fangsheng Pharmaceutical's subsidiary has received approval for the clinical trial of a new drug, Relugolix, which is a GnRH receptor antagonist for treating advanced prostate cancer [1] Group 1: Drug Development and Approval - The clinical trial approval notification for Relugolix was issued by the National Medical Products Administration [1] - The total investment in the drug development project has reached approximately 3.89 million yuan (around 0.6 million USD) as of the announcement date [1] Group 2: Market Potential - The global sales of Relugolix in 2023 amounted to 300 million USD, reflecting a year-on-year growth rate of 58.6% [1] - The drug development process, from research to clinical trial approval and production, is lengthy and involves multiple stages, which can be affected by various uncertainties [1]